IGF-1 (Insulin-like Growth Factor 1), Research Reference

IGF-1 (Insulin-like Growth Factor 1) is a 70-amino acid single-chain peptide and the primary mediator of growth hormone’s anabolic effects in peripheral tissues. Produced predominantly in the liver in response to GH receptor activation, IGF-1 is also synthesised locally in muscle, bone, cartilage, and other tissues. Research has investigated IGF-1 extensively for its roles in muscle hypertrophy, skeletal growth, satellite cell activation, and recovery from tissue injury. IGF-1 LR3, a synthetic long-acting analogue, is the form most commonly discussed in anecdotal research accounts due to its substantially extended half-life.

Quick Reference

Parameter	Native IGF-1	IGF-1 LR3
Full name	Insulin-like Growth Factor 1	Long R3 Insulin-like Growth Factor 1
Amino acids	70	83 (13-aa N-terminal extension)
Key modification	Endogenous sequence	R3 substitution, N-terminal extension
Half-life	~10 minutes (plasma)	~12–15 hours
IGFBP binding	High	Substantially reduced
Relative potency	Reference	~2–3× in some assays
Common reported doses	Less common due to short half-life	20–100 mcg
Administration routes	Subcutaneous, intramuscular	Subcutaneous, intramuscular
Storage (lyophilized)	Refrigerator (2-8°C)	Refrigerator (2-8°C)
Storage (reconstituted)	Refrigerated; use within 28 days	Refrigerated; use within 28 days

Overview

The GH–IGF-1 Axis

Growth hormone (GH) is secreted in pulsatile bursts from the anterior pituitary gland and acts on receptors throughout the body, with the liver as the primary site of IGF-1 production. GH receptor activation in hepatocytes stimulates the synthesis and secretion of IGF-1 into circulation, where it is largely bound to a family of IGF-binding proteins (IGFBPs), primarily IGFBP-3. Only a small fraction of circulating IGF-1 is free and biologically active at any given moment.

IGF-1 then mediates the majority of GH’s anabolic and somatic growth effects:

Stimulating muscle protein synthesis via the PI3K-Akt-mTOR pathway
Activating satellite cells (muscle stem cells), promoting muscle hypertrophy and repair
Driving longitudinal bone growth at epiphyseal growth plates
Promoting cartilage matrix synthesis and chondrocyte proliferation
Inhibiting apoptosis (cell death), supporting cell survival across multiple tissue types
Promoting glucose uptake in muscle and adipose tissue via Akt signalling

IGF-1 also exerts negative feedback on GH secretion at the pituitary and hypothalamus, forming a regulatory loop. Locally produced IGF-1 within muscle and bone (autocrine and paracrine signalling) contributes independently of circulating hepatic IGF-1, and this local production is itself stimulated by resistance exercise and GH signalling.

Native IGF-1 vs IGF-1 LR3

The principal pharmacokinetic limitation of native IGF-1 in a research context is its extremely short plasma half-life of approximately 10 minutes, driven primarily by rapid IGFBP binding and hepatic clearance. This makes native IGF-1 impractical for most research applications without continuous infusion.

IGF-1 LR3 was developed to address this limitation. The R3 substitution (arginine at position 3) and the 13-amino acid N-terminal extension together reduce IGFBP-3 and IGFBP-1 binding affinity by approximately 1,000-fold compared to native IGF-1. This dramatically increases the free peptide fraction in circulation and extends the functional half-life to approximately 12 to 15 hours. IGF-1 LR3 retains full affinity for the IGF-1 receptor and has been reported to be approximately 2 to 3 times more potent than native IGF-1 in certain in vitro cell proliferation assays.

As a result, IGF-1 LR3 is the predominant form discussed in anecdotal research accounts, and the protocols described in this page refer primarily to IGF-1 LR3 unless otherwise noted.

Receptor Mechanism

IGF-1 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase structurally homologous to the insulin receptor. Ligand binding activates two primary intracellular signalling cascades:

PI3K-Akt-mTOR pathway: promotes protein synthesis, cell growth, glucose uptake, and inhibits apoptosis
Ras-MAPK-ERK pathway: promotes cell proliferation and differentiation, including satellite cell activation

IGF-1R also engages hybrid receptors formed with insulin receptors, and IGF-1 exhibits partial affinity for the insulin receptor itself at higher concentrations. This cross-reactivity underlies the significant hypoglycaemic potential of IGF-1 and IGF-1 LR3.

Reported Protocols

The following information represents commonly reported research ranges drawn from anecdotal accounts and available research literature. These are not medical recommendations.

IGF-1 LR3 Protocol

IGF-1 LR3 is the most commonly discussed form in anecdotal research accounts due to its extended half-life, which permits once-daily or post-workout administration. Commonly reported doses range from 20 mcg to 100 mcg per day, administered subcutaneously or intramuscularly.

Low range: 20–40 mcg per day; most commonly reported in accounts prioritising tolerance assessment and minimising hypoglycaemic risk
Mid range: 50–80 mcg per day; the most frequently discussed range in anecdotal accounts
Upper range: 100 mcg per day; less commonly reported, associated with increased hypoglycaemic risk and reported side effects
Cycle duration: 4 to 8 weeks is the most commonly described cycle length; longer cycles are described but associated with concerns about chronic IGF-1 elevation
Off-period: Anecdotal accounts commonly describe equivalent or longer off-periods between cycles, citing concerns about receptor desensitisation and cumulative side effects

Timing Considerations

Anecdotal research accounts describe two primary timing strategies for IGF-1 LR3:

Post-workout administration: Injection following resistance exercise, with the rationale that elevated local blood flow and nutrient delivery may enhance uptake at the target muscle site; commonly paired with post-workout carbohydrate and protein intake, which also partially attenuates hypoglycaemic risk
Morning fasted administration: Less commonly reported; carries a higher hypoglycaemic risk than post-workout timing given the absence of concurrent carbohydrate intake; accounts describing this approach emphasise immediate consumption of fast-absorbing carbohydrates following injection

Hypoglycaemia Mitigation

Hypoglycaemia is the most consistently reported acute concern with IGF-1 LR3. Anecdotal accounts commonly describe the following precautions:

Consuming 20 to 40 grams of fast-absorbing carbohydrates immediately before or after injection
Avoiding IGF-1 LR3 administration in a fully fasted state without carbohydrate on hand
Starting at the lower end of the dose range (20 mcg) to assess individual sensitivity before increasing
Having a glucose source (juice, glucose tablets) available during and after the injection window

Native IGF-1 Protocol

Native IGF-1 is less commonly described in anecdotal research accounts due to its short plasma half-life of approximately 10 minutes, which limits practical application without continuous infusion. Where described, commonly reported doses range from 20 to 100 mcg administered subcutaneously or intramuscularly, at multiple time points throughout the day, though the pharmacokinetic rationale for this approach is limited by rapid clearance and IGFBP binding. For most research contexts discussed in the anecdotal community, IGF-1 LR3 is the preferred form.

Injection Site Selection

Subcutaneous injection is the most commonly reported route, typically performed in the abdominal region or the thigh. Intramuscular injection into the target muscle group is described in some accounts, particularly in the post-workout timing context. Site rotation with each injection is consistently recommended in anecdotal accounts to minimise local tissue response.

Reported Effects

The following effects have been reported in preclinical research, clinical trials, and anecdotal accounts. This list reflects the research landscape and does not constitute confirmed clinical outcomes for any specific individual.

Muscle Hypertrophy and Protein Synthesis

Research has characterised IGF-1 as a potent anabolic signal in skeletal muscle through two complementary mechanisms:

Direct stimulation of muscle protein synthesis via PI3K-Akt-mTOR activation, increasing the rate at which amino acids are incorporated into contractile proteins
Activation of muscle satellite cells (Sc), which are quiescent muscle stem cells; activated satellite cells proliferate, differentiate, and fuse with existing muscle fibres, increasing myonuclear number and hypertrophic capacity

Anecdotal accounts in the research community describe subjective increases in muscle fullness, improved nitrogen retention, and enhanced recovery between training sessions. These reports are consistent with the known biology of IGF-1 signalling in muscle tissue, though individual responses vary considerably.

Bone and Cartilage Effects

IGF-1 is a key regulator of skeletal growth. Research has investigated IGF-1 for:

Stimulation of chondrocyte proliferation and differentiation at growth plates
Promotion of osteoblast activity and bone matrix synthesis
Potential improvements in bone mineral density in research contexts examining GH deficiency or osteoporosis

Anecdotal accounts describe improved joint comfort and connective tissue recovery, though the mechanistic basis for joint-specific effects and the extent to which they differ from systemic protein synthesis enhancement is not well characterised.

Recovery from Injury

Research and anecdotal accounts have investigated IGF-1 in the context of recovery from muscle and connective tissue injury. The satellite cell activation mechanism is considered particularly relevant here, as satellite cells are central to muscle repair following mechanical damage. Preclinical research has reported accelerated muscle regeneration following IGF-1 administration in animal models.

Anti-apoptotic and Cell Survival Effects

IGF-1 is a well-characterised survival factor across multiple tissue types. Akt activation downstream of IGF-1R phosphorylates and inactivates pro-apoptotic proteins (including Bad and caspase-9), promoting cell survival. This effect is relevant in the context of tissue repair and has also been investigated in neurological research contexts, where IGF-1 has been studied for potential neuroprotective properties.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. This list does not constitute a comprehensive safety profile and should not be interpreted as predictive of individual outcomes.

Side Effect	Frequency Reported	Notes
Hypoglycaemia (low blood glucose)	Common; most significant acute concern	Shares mechanism with insulin; consume carbohydrates around injection time
Fluid retention / oedema	Commonly reported	Often presents as puffiness in hands, feet, or face; generally transient
Joint pain or aches	Occasionally reported	May relate to fluid distribution changes; distinct from direct anti-inflammatory effects
Injection site discomfort	Common (any subcutaneous or IM injection)	Mild; generally resolves within hours
Headache	Occasionally reported	Possibly related to blood glucose fluctuation
Fatigue or lightheadedness	Occasionally reported	Often concurrent with mild hypoglycaemic episodes
Acromegalic features (jaw, brow, hands)	Reported with prolonged high-dose use	Analogous to effects of chronic GH excess; generally associated with long-term supraphysiological exposure
Visceral organ enlargement	Reported with prolonged high-dose use	Concern raised in anecdotal accounts for extended, high-dose cycles
Paradoxical insulin resistance	Reported with chronic use	Contrasts with acute glucose-lowering effect; mechanism involves compensatory downregulation
Theoretical increased oncogenic risk	Flagged in research and epidemiological literature	IGF-1 is mitogenic; chronic supraphysiological levels associated in observational studies with certain cancers

Hypoglycaemia: Additional Context

Hypoglycaemia warrants specific attention because it can occur rapidly and may be severe. IGF-1 and insulin share structural homology and converge on the PI3K-Akt pathway, which governs GLUT4 transporter translocation and glucose uptake in muscle and adipose tissue. IGF-1 LR3, due to its long half-life, produces a sustained glucose-lowering effect that can persist for hours after injection.

Anecdotal accounts consistently describe symptoms including shakiness, sweating, rapid heartbeat, mental confusion, and in severe cases, loss of consciousness. The risk is elevated in fasted states, in smaller individuals, and at the upper end of the dose range. Starting at lower doses and always having a fast-absorbing carbohydrate source available are the most commonly reported precautionary measures.

Storage & Handling

Lyophilized Powder (Unreconstituted)

Refrigerator (2-8°C): Preferred storage condition; commonly reported as stable for 12 months or more when stored properly and protected from light
Freezer: Acceptable for long-term storage of the dry lyophilized powder; avoid repeated freeze-thaw cycles, which can degrade peptide structure
Room temperature: Short-term exposure during shipping is generally described as tolerable, but prolonged room temperature storage is not recommended
Light sensitivity: Store in an opaque or amber vial away from direct light exposure; IGF-1 is sensitive to UV degradation

Reconstituted Solution

Refrigerator (2-8°C): Reconstituted IGF-1 LR3 is commonly reported as stable for up to 28 days when reconstituted with bacteriostatic water and stored refrigerated; some accounts describe shorter windows of 14 days, particularly for native IGF-1
Do not freeze a reconstituted solution; freezing and thawing a liquid peptide solution degrades the peptide and reduces potency
Bacteriostatic water is the commonly reported diluent for multi-use vials, as the benzyl alcohol preservative extends usable stability; sterile water for injection may be used for single-use preparations
Discard if the solution becomes cloudy, discoloured, or shows particulate matter; IGF-1 solutions should be clear and colourless

Reconstitution

Add the chosen diluent slowly to the lyophilized vial, directing the liquid along the inside wall rather than directly onto the peptide powder. Swirl gently; do not shake. Allow several minutes for complete dissolution. Record the reconstitution date and volume added to calculate concentration per injection volume. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

What is the difference between native IGF-1 and IGF-1 LR3? Native IGF-1 is a 70-amino acid endogenous peptide with a plasma half-life of approximately 10 minutes. The majority of circulating IGF-1 is bound to IGF-binding proteins (IGFBPs), which limit its bioavailability and extend its effective duration in vivo. IGF-1 LR3 is a synthetic analogue featuring an arginine substitution at position 3 and a 13-amino acid N-terminal extension. These modifications substantially reduce IGFBP binding affinity, resulting in a far higher proportion of free, biologically active peptide in circulation and extending the half-life to approximately 12 to 15 hours. IGF-1 LR3 is also reported to be approximately 2 to 3 times more potent than native IGF-1 in certain in vitro assays, making it the more commonly discussed form in anecdotal research accounts.

Why is hypoglycaemia a concern with IGF-1? IGF-1 and insulin share structural homology and both engage receptors within the same receptor tyrosine kinase superfamily. IGF-1 binds its own IGF-1 receptor (IGF-1R) but also exhibits partial cross-binding affinity for the insulin receptor, particularly at higher concentrations. Through activation of the PI3K-Akt signalling pathway, which is shared between IGF-1R and the insulin receptor, IGF-1 promotes cellular glucose uptake and can lower blood glucose levels. This effect is more pronounced with IGF-1 LR3 due to its longer half-life and higher free-peptide fraction. Anecdotal research accounts consistently report consuming 20 to 40 grams of fast-absorbing carbohydrates around the time of injection to attenuate hypoglycaemic episodes, particularly in fasted states.

How does IGF-1 relate to growth hormone in the GH–IGF-1 axis? Growth hormone (GH) is secreted in pulsatile bursts from the anterior pituitary gland and acts on receptors throughout the body, most prominently in the liver. Hepatic GH receptor activation stimulates the synthesis and secretion of IGF-1, which then mediates the majority of GH’s anabolic and growth-promoting effects in peripheral tissues. This relationship is described as the GH–IGF-1 axis. IGF-1 also exerts negative feedback on GH secretion at the pituitary and hypothalamic level, forming a regulatory loop. Locally produced IGF-1 in muscle, bone, and other tissues (autocrine and paracrine IGF-1) contributes independently of circulating hepatic IGF-1, and this local production is also influenced by GH signalling. Peptides that stimulate GH release, such as CJC-1295, Ipamorelin, Sermorelin, and Hexarelin, therefore indirectly raise endogenous IGF-1 levels through this axis.

What is the risk of prolonged IGF-1 use in research contexts? Anecdotal research accounts and the broader endocrinological literature identify several concerns associated with prolonged or high-dose IGF-1 use. IGF-1 is a potent mitogenic signal that promotes cell proliferation and inhibits apoptosis; chronic elevation of IGF-1 has been associated in epidemiological studies with increased risk of certain cancers, particularly colorectal, prostate, and breast cancers, though causal directionality remains debated. Prolonged supraphysiological IGF-1 exposure is also associated with acromegalic features including jaw and brow changes, soft tissue swelling, and visceral organ enlargement, effects analogous to those observed in acromegaly. Paradoxical insulin resistance has been reported with chronic IGF-1 use, contrary to the acute glucose-lowering effect. Most anecdotal accounts in the research community describe cycle lengths of 4 to 8 weeks with off-periods to limit cumulative exposure.

Goals: Muscle Growth | Performance

Class: Growth Factor Peptides

Comparisons: IGF-1 vs MK-677

GH axis peptides (upstream): CJC-1295 | Ipamorelin | Sermorelin | Hexarelin

References & Further Reading

Jones JI, Clemmons DR. (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews, 16(1), 3–34. PubMed →
LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. (1995). Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Reviews, 16(2), 143–163. PubMed →
Rosenfeld RG, Roberts CT Jr. (Eds.). (1999). The IGF System: Molecular Biology, Physiology, and Clinical Applications. Humana Press.
Clemmons DR. (2007). Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nature Reviews Drug Discovery, 6(10), 821–833. PubMed →
Frystyk J. (2004). Free insulin-like growth factors: measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Hormone & IGF Research, 14(5), 337–375. PubMed →
Rinderknecht E, Humbel RE. (1978). The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. Journal of Biological Chemistry, 253(8), 2769–2776. PubMed →
Tomas FM, et al. (1992). Prolonged administration of IGF-I/IGFBP-3 complex stimulates growth and maintains anabolic actions. Journal of Endocrinology, 133(3), 329–344. PubMed →